Literature DB >> 8187952

Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells.

C H Chien1, F F Wang, T C Hamilton.   

Abstract

NIH:OVCAR-3 is a human ovarian cancer cell line that expresses a moderate amount of estrogen receptors, 28 fmol/mg protein. We have found that estrogen at a concentration of 10(-7) M induced a 2.3-fold increase in the growth of NIH:OVCAR-3 cells after 48 h stimulation. A 4-fold increase in c-myc mRNA expression at 30 min and a 7.5-fold increase at 50 min post-induction with estradiol were observed. Nuclear run-on analysis indicated that c-myc transcripts increased 4-fold within 10 min of estrogen addition. The half-life of c-myc mRNA was 64 min +/- 5 min and was not affected by estrogen. Antisense oligonucleotide to c-myc specifically inhibited the estrogen stimulated c-myc protein expression as well as the growth of NIH:OVCAR-3 cells. A control ovarian cancer cell line OC-3-VGH that had few estrogen receptors (1 fmol/mg protein) did not respond to estrogen in growth; however, these cells respond to estrogen with a 1.5-fold increase in c-myc mRNA. The stability of c-myc mRNA of these cells was not affected by estrogen. Our results indicate that transcriptional induction of c-myc expression by estrogen plays a critical role in the proliferation of NIH:OVCAR-3 cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187952     DOI: 10.1016/0303-7207(94)90140-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  13 in total

1.  MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Authors:  Karina E Hew; Philip C Miller; Dorraya El-Ashry; Jun Sun; Alexandra H Besser; Tan A Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B Mills; Joyce M Slingerland; Fiona Simpkins
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer.

Authors:  Xiang-Yun Liu; Xin Su; Chen-Jing Xie; Lei Li; Jian-Yan Yan; Zu-Yue Sun
Journal:  Exp Ther Med       Date:  2015-05-26       Impact factor: 2.447

Review 3.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

Review 4.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

5.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells.

Authors:  G M Clinton; C Rougeot; J Derancourt; P Roger; A Defrenne; S Godyna; W S Argraves; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

6.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha.

Authors:  Se-Hyung Park; Lydia W T Cheung; Alice S T Wong; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2008-06-11

7.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

Review 8.  The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.

Authors:  Kyong Hye Joung; Jae-Wook Jeong; Bon Jeong Ku
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

9.  Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Authors:  Sergio Eduardo Perniconi; Manuel de Jesus Simões; Ricardo Dos Santos Simões; Mauro Abi Haidar; Edmund C Baracat; Jose Maria Soares
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

10.  The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Authors:  Defeng Xu; Tzu-Hua Lin; Chiuan-Ren Yeh; Max A Cheng; Lu-Min Chen; Chawnshang Chang; Shuyuan Yeh
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.